Targeting cancer Flashcards

1
Q

What is a hereditary cancer?

A

A germline mutation: one that is present in gametes, present in every cell of offspring
- usually in tumour suppressor genes

Usually inherit a predisposition to cancer with the risk increasing over lifetime

Most cancers are polygenic (+infection + environment) although exceptions exist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is retinoblastoma?

What is the causative mutation?

How does the presentation differ between the familial and sporadic form?

A

A rare childhood cancer

Tumour caused by mutations in Rb tumour suppressor gene

Familial form (40%) affects younger children and is often bilateral, may be multifocal
Sporadic form (60%) is unilateral
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the difference in the distribution of the mutant protein gene in retinoblastoma in the familial and sporadic form

What does this mean for the likelihood of tumorgenesis?

A

Familial form

  • child inherits a germline copy of mutant Rb gene: every retinal cell bears this mutant allele
  • high probability of spontaneous mutation in other allele

Sporadic form

  • spontaneous mutations in both copies of the Rb gene must occur in the same retinal cell for tumorgenesis
  • low probabiltiy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the function of the Rb gene?

A

Encodes the retinoblastoma protein pRb

  • regulates cell cycle progression
  • inhibits transcription of cell cycle proteins by binding to the transcription factor E2F
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How does a mutation in the Rb gene contribute to carcinogenesis?

A

In the absence of functional pRb:

  • cell cycle progression uncontrolled
  • DNA replication even in presence of damaged DNA
  • increases replication rates
  • predisposes to further mutations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are BRCA1 and BRCA2?

A

Large nuclear proteins involved in repair of DNA double strand breaks

BRCA1 is additionally a cell cycle checkpoint signaller and involved in transcriptional regulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why are BRCA1 and BRCA2 deficient cells at an increased risk of further mutations?

A

Cells deficient in either protein show “genomic instability”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the lifetime risk of cancer in those with BRCA1 and BRCA2 mutations?

A

BRCA 1

  • 94% of breast or ovarian
  • 60-80% of breast cancer
  • increased risk of colon and prostate cancer

BRCA2

  • breast cancer risk: 60-80%
  • ovarian cancer risk: 10-50%

Together account for 5-10% of all breast cancers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is “risk”?

A
  • relative to population risk

- it will vary between populations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What factors are used to calculate risk?

A
  • age
  • FHx
  • personal risk factors
  • use a risk estimate models
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is does it mean to be

a) low risk
b) moderate risk
c) high risk

A

a) = population risk
In breast cancer that is <3% aged 40-50/lifetime risk <17%

b) 3-8% aged 40-50
lifetime risk 17-30%

c) risk >8% aged 40-50
lifetime risk >30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How are patients at low risk of breast cancer managed?

A
  • mammographic screening from age 50
  • breast awareness
  • lifestyle information
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How are patients at moderate risk of breast cancer managed?

A

under 40
- information, counselling

40-49
- annual mammography

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How are patients at high risk of breast cancer managed?

A
  • refer to specialist clinic, genetic counselling

- genetic testing IF affected family member agrees

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Give three “high risk” factors

A
  • Jewish ancestry
  • multiple cancers at young age
  • two relatives with BrCa <50
  • three relative with BrCa <60
  • four relatives with BrCa any age
  • ovarian cancer + BrCa<50
  • bilateral BrCa <50
  • male BrCa + BrCa <50
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Consider genetic testing

  • In a family you suspect to have heriditary BRCA gene. Who must be approached for testing first?
  • What does the testing involve?
A
  • The family member who is affected (has cancer) must agree and a faulty BRCA1/2 must be identified first. If found look for the same mutation in family members after genetic counselling
  • Sequence entire gene looking for mutations
17
Q

How can we reduce the risk of cancer in the BRCA+ population?

A

Prophylactic treatment

  • surgical: breasts, ovaries
  • medical tamoxifen

Surveillance

  • mammography, MRI
  • CA-125
  • pelvic USS
18
Q

Describe synthetic lethality as applied to PARP inhibitors in cancer treatments

A

BRCA1/2 play a role in signalling and repairing DNA double strand breaks.

PARP is another DNA repair repair protein which fixes single strand breaks.

In people with faulty BRCA proteins, the partial repair of faulty DNA is due to PARP
(they fix the damage such that an overwhelming amount of DNA damage doesnt trigger cellular apoptosis)

PARP inhibitors cause the cell to trigger its own death as the DNA is not repaired at all.

19
Q

What are the key signs of chronic myeloid leukaemia?

A
  • High WCC

- Splenomegaly

20
Q

How does the philadelphia chromosome arise?

What is it?

A

Reciprocal translocation between the 9th and 22nd chromosome

Forms a fusion gene: BCR-ABL which encodes a tyrosine kinase and acts as an oncogene

21
Q

How is Imatinib a targeted treatment?

A

It is a tyrosine kinase inhibitor so inhibits the function of the TK encoded by the BCR-ABL gene.

Imatinib competitively binds to the kinase domain meaning its substrate cannot enter the kinase site.

This discourages the downstream effects of the tyrosine kinase such as proliferation

Survival is now >95% at 5 years for CML patients